Plant Name: Croton megistocarpus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| RECQL; GLA; TDP1; BLM; HPGD; HSD17B1; AKR1B1; HSD17B2; ALDH1A1; | |
| CA2; CA1; CA12; CA9; CA5B; CA3; CA14; CA7; CA5A; CA4; CA6; | |
| ESR1; ESR2; | |
| KDM4E; | |
| ALDH2; | |
| HIF1A; TP53; NFKB1; | |
| FUT7; | |
| SLCO1B3; SLCO1B1; | |
| RAB9A; LMNA; NPC1; MAPT; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.886E-10 | 4.835E-07 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.569E-10 | 8.662E-07 | CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.640E-10 | 1.254E-06 | BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.009E-08 | 1.156E-05 | CYP19A1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.391E-07 | 1.165E-04 | CA2, CA4, CA9, HPGD, SLCO1B1, SLCO1B3, TSHR |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.659E-07 | 1.338E-04 | CYP19A1, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.247E-07 | 2.209E-04 | CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 7.957E-07 | 5.096E-04 | BLM, RECQL, TP53 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.135E-06 | 6.840E-04 | CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.162E-06 | 6.840E-04 | CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.205E-06 | 6.907E-04 | CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.665E-27 | 3.625E-23 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.074E-06 | 1.096E-03 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.074E-06 | 1.096E-03 | CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.693E-06 | 1.303E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.685E-06 | 2.082E-03 | CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 4.616E-06 | 2.082E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.237E-05 | 4.898E-03 | CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.383E-05 | 5.191E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.383E-05 | 5.191E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.107E-05 | 7.400E-03 | BLM, CA2, CA9, CYP1B1, ESR1, HPGD, NFKB1, NPC1, TP53 |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 2.745E-05 | 8.715E-03 | AKR1B1, ALDH1A1, ALDH2, CYP1B1, CYP3A4, NPC1 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.762E-05 | 8.715E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.762E-05 | 8.715E-03 | CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 3.015E-05 | 9.379E-03 | CYP19A1, CYP3A4, ESR1 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 3.163E-05 | 9.701E-03 | CYP1B1, GLA, HIF1A, MAPT, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.963E-21 | 9.758E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.809E-19 | 9.848E-16 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.027E-26 | 1.252E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.348E-07 | 8.220E-06 | HSD17B1; HSD17B2; CYP1B1; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.606E-06 | 1.467E-04 | HSD17B1; HSD17B2; CYP1B1; CYP19A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.315E-05 | 3.347E-04 | CYP2C9; CYP2D6; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.646E-05 | 3.347E-04 | CYP2C9; CYP2D6; CYP1B1; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.474E-05 | 3.347E-04 | SLCO1B1; CA2; SLCO1B3; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.609E-05 | 4.547E-04 | CYP2C9; CYP1B1; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.907E-04 | 2.585E-03 | CYP2C9; FUT7; ALDH2; HSD17B1; HSD17B2; ALDH1A1; AKR1B1; CYP2C19; CYP3A4; CYP19A1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.029E-05 | 4.619E-04 | CYP2C9; CYP3A4; CYP2C19 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 2.579E-04 | 3.147E-03 | ALDH2; AKR1B1; GLA |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.643E-04 | 4.721E-03 | ESR1; NFKB1; ESR2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.436E-04 | 3.810E-03 | CYP2C9; ALDH1A1; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.674E-03 | 1.459E-02 | CYP2C9; CYP2D6; CYP2C19 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.943E-03 | 1.482E-02 | TP53; ESR1; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.156E-03 | 1.947E-02 | LMNA; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.909E-03 | 1.947E-02 | RAB9A; TP53; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.843E-03 | 4.315E-02 | TP53; HIF1A; ESR1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 6.361E-03 | 3.696E-02 | HPGD; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.482E-03 | 4.315E-02 | TP53; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 7.517E-03 | 4.169E-02 | CYP2C9; CYP2C19 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.804E-03 | 1.467E-02 | AKR1B1; GLA |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.592E-03 | 1.860E-02 | ALDH2; AKR1B1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.192E-03 | 1.947E-02 | ALDH2; CYP1B1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.731E-03 | 4.315E-02 | TP53; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.030E-02 | 4.831E-02 | TP53; NFKB1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.059E-03 | 9.940E-03 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ALDH2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ALDH2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; ESR1; ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; CA9; NFKB1; ESR1; ESR1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |